Natco Pharma receives EIR from US FDA for Visakhapatnam manufacturing plant

The USFDA classified its August inspection as Voluntary Action Indicated (VAI), meaning the company must address the observations but faces no planned regulatory action. The development comes after Natco reported a 61% year-on-year decline in Q2 net profit.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Natco Pharma (NATCOPHARM).
- Category: Results.
Why it matters
A routine update for Natco Pharma. Use the price and stock snapshot to gauge how the market is responding.










